Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 225,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $20.51, for a total transaction of $4,614,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Scopia Capital Management Lp also recently made the following trade(s):

  • On Thursday, November 29th, Scopia Capital Management Lp sold 50,000 shares of Acorda Therapeutics stock. The shares were sold at an average price of $20.20, for a total transaction of $1,010,000.00.
  • On Thursday, October 11th, Scopia Capital Management Lp sold 143,576 shares of Acorda Therapeutics stock. The shares were sold at an average price of $16.98, for a total transaction of $2,437,920.48.
  • On Tuesday, October 9th, Scopia Capital Management Lp sold 153,858 shares of Acorda Therapeutics stock. The shares were sold at an average price of $17.28, for a total transaction of $2,658,666.24.
  • On Tuesday, October 2nd, Scopia Capital Management Lp sold 32,649 shares of Acorda Therapeutics stock. The shares were sold at an average price of $18.89, for a total transaction of $616,739.61.
  • On Thursday, October 4th, Scopia Capital Management Lp sold 126,464 shares of Acorda Therapeutics stock. The shares were sold at an average price of $19.15, for a total transaction of $2,421,785.60.
  • On Thursday, September 6th, Scopia Capital Management Lp sold 13,829 shares of Acorda Therapeutics stock. The shares were sold at an average price of $27.82, for a total transaction of $384,722.78.
  • On Tuesday, September 4th, Scopia Capital Management Lp sold 200 shares of Acorda Therapeutics stock. The shares were sold at an average price of $29.00, for a total transaction of $5,800.00.

Shares of ACOR stock opened at $18.55 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.95 and a current ratio of 4.03. The company has a market cap of $971.62 million, a price-to-earnings ratio of 17.84 and a beta of 1.45. Acorda Therapeutics Inc has a 52 week low of $15.60 and a 52 week high of $36.35.

Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.02 by $0.15. The firm had revenue of $142.80 million for the quarter, compared to the consensus estimate of $82.74 million. Acorda Therapeutics had a negative net margin of 24.88% and a positive return on equity of 13.72%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the company posted $0.43 EPS. On average, analysts forecast that Acorda Therapeutics Inc will post 0.08 EPS for the current year.

ACOR has been the topic of a number of analyst reports. HC Wainwright set a $28.00 price target on shares of Acorda Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 24th. BidaskClub upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 8th. TheStreet downgraded shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, October 5th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Acorda Therapeutics in a research report on Friday, October 12th. Finally, Stifel Nicolaus cut their price target on shares of Acorda Therapeutics from $25.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, October 5th. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $26.56.

A number of hedge funds have recently made changes to their positions in ACOR. Renaissance Technologies LLC raised its holdings in Acorda Therapeutics by 87.3% during the 3rd quarter. Renaissance Technologies LLC now owns 1,275,400 shares of the biopharmaceutical company’s stock worth $25,062,000 after buying an additional 594,500 shares during the period. Vanguard Group Inc. raised its holdings in Acorda Therapeutics by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,384,536 shares of the biopharmaceutical company’s stock worth $105,806,000 after buying an additional 545,689 shares during the period. Acadian Asset Management LLC raised its holdings in Acorda Therapeutics by 500.7% during the 3rd quarter. Acadian Asset Management LLC now owns 455,987 shares of the biopharmaceutical company’s stock worth $8,961,000 after buying an additional 380,072 shares during the period. Baker BROS. Advisors LP acquired a new stake in Acorda Therapeutics during the 2nd quarter worth approximately $4,968,000. Finally, Prudential Financial Inc. raised its holdings in Acorda Therapeutics by 57.5% during the 3rd quarter. Prudential Financial Inc. now owns 443,131 shares of the biopharmaceutical company’s stock worth $8,707,000 after buying an additional 161,853 shares during the period.

WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/insider-selling-acorda-therapeutics-inc-acor-major-shareholder-sells-4614750-00-in-stock/2663707.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

See Also: Systematic Risk and Investors

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.